NCT05247684

AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC

Phase II Clinical Study of AK112, an Anti-PD-1 and VEGF Bispecific Antibody, Alone or in Combination With Chemotherapy for the Neoadjuvant/Adjuvant Treatment of Resectable Non-small Cell Lung Cancer

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 90 (actual)
• Sponsor: Akeso · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

AK112, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable NSCLC

Detailed description

Phase II clinical study of AK112, an anti-PD-1 and VEGF bispecific antibody, alone or in combination with chemotherapy for the neoadjuvant/adjuvant treatment of resectable non-small cell lung cancer

Conditions

• Resectable Non-small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	AK112	IV infusion
DRUG	Carboplatin	IV infusion
DRUG	Cisplatin	IV infusion
DRUG	Paclitaxel	IV infusion

Timeline

• Start date: 2022-02-20
• Primary completion: 2025-08-18
• Completion: 2026-12-31
• First posted: 2022-02-21
• Last updated: 2026-03-05

Locations

1 site across 1 country: China